Growth momentum Veracyte is expanding its diagnostic test portfolio with launches including Prosigna LDT, TrueMRD recurrence-monitoring for muscle-invasive bladder cancer, and MRD testing plans, signaling opportunities to cross-sell additional assays to existing oncology clients and IDN networks.

High-value deals Recent quarterly revenue growth and raised full-year guidance indicate expanding payer acceptance and adoption of their diagnostic tests, presenting opportunities to target hospital systems, cancer centers, and specialty clinics with bundled or SDR-focused solutions.

Strategic leadership New chief of development and technology officer joining to oversee end-to-end product development suggests a priority on faster time-to-market and enhanced software and bioinformatics offerings, ideal for partnerships in product co-development and integrated analytics platforms.

MRD opportunity Plans to launch minimal residual disease MRD testing at major conferences indicate a push into precision monitoring; sales efforts can target oncology groups focused on post-treatment surveillance and recurrence risk stratification.

Data-driven sell Active participation in ASCO events and data releases across uro-oncology and breast cancer spaces create compelling evidence for clinicians; leverage case studies, health economics, and real-world performance data to drive adoption in cancer care pathways.